Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

Author(s):
Willemze, R. (0000-0001-9115-3106); Suciu, S.; Muus, P.; Halkes, C.J.M.; Meloni, G.; Meert, L.; Karrasch, M.; Rapion, J.; Vignetti, M.; Amadori, S.; Witte, T. de; Marie, J.P.
Published
2014
Publication type
Article / Letter to editor
Acute myeloid leukemiaClofarabinePhase I dose finding study
Date issued
2014-06-30
Language
English
Is part of
Annals of Hematology (2014), Vol. 93, no. 6, p. 965-975
hdl
1887/104431
doi
10.1007/s00277-014-2056-6